Needham analyst Michael Matson assigned a Buy rating to Zimmer Biomet Holdings (ZBH) today and set a price target of $162.00. The company’s shares closed last Tuesday at $130.64.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.8% and a 58.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $141.67 average price target, representing an 9.0% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $161.11 and a one-year low of $74.37. Currently, Zimmer Biomet Holdings has an average volume of 1.47M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
